Trials / Unknown
UnknownNCT06038994
Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the prognostic value of surem TRAF3IP2 levels in patients with acute myocardial infarction
Detailed description
Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients diagnosed with acute myocardial infarction who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the major adverse cardiac events will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | This is an obvertional study, and there is no intervention. |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2024-04-30
- Completion
- 2025-04-30
- First posted
- 2023-09-15
- Last updated
- 2023-09-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06038994. Inclusion in this directory is not an endorsement.